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Purpose: To develop simple, rapid and selective spectrophotometric methods for the determination of 
cilostazol in tablet dosage form. 
Methods: Cilostazol was dissolved in 50 % methanol and its absorbance was scanned by ultraviolet 
(UV) spectrophotometry. Both linear regression equation and standard absorptivity were calculated and 
both methods were validated as per ICH guidelines. Cilostazol was determined in tablet dosage form 
using these validated methods. 
Results: The λmax of cilostazol was 258.2 nm in 50 % methanol. Beer-Lambert’s law was obeyed in the 
concentration range of 0 – 25 µg/ml and standard absorptivity was 420.2 dL.g-1.cm-1. The numerical 
values for all the validation parameters were within acceptable limits. The results of cilostazol tablet 
determination by linear regression equation and standard absorptivity methods indicate purity of 100.0 - 
102.4 and 98.7 - 101.1 % with standard deviations of 0.611 and 0.592, respectively. Comparing the 
methods at 99 % confidence limit, the F-test value was found to be 1.065. 
Conclusion: These validated methods may be useful for routine analysis of cilostazol as bulk drugs, in 
dosage forms as well as in dissolution studies in the pharmaceutical industry. 
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INTRODUCTION 
 
Cilostazol, whose chemical name is 6-[4-(1-
cyclohexyl-1H-tetrazol-5-y1) butoxy]-3, 4- 
dihydro-2 (1H) – quinolinone (see Fig 1), is a 
quinolinone derivative that inhibits cellular 
phosphodiesterase III, and is used for the 
inhibition of platelet aggregation and as a 











Fig. 1: Structure of cilostazol 
 
The literature reveals that chromatographic 
methods are employed in the determination 
of cilostazol in tablet dosage form and human 
plasma and, to the best of our knowledge, no 
spectrophotometric method has yet been 
reported for this compound in tablet form [5-
6]. However, the degradation profile and RP-
HPLC analysis of cilostazol in tablet dosage 
form has been reported [7]. Compared to 
chromatographic methods, spectrophoto-
metric methods are suitable for routine 
analysis because it is economic, rapid, 
simple, maintenance-free, and show 
comparable accuracy and precision with 
HPLC methods. Therefore, the object of the 
present work was to develop 
spectrophotometric methods for the 




Instruments, reagents and chemicals  
 
Ultraviolet spectrophotometer (1700 series, 
Shimadzu) and UV-VIS double beam 
spectrophotometer 2201 (Systronics) with 1 
cm matched quartz cells were used for the 
measurement of absorbance. Shimadzu-Ax-
200 electronic balance was used for weighing 
the samples, and class “A” volumetric 
glassware were used.  
 
Working standard (WS) of cilostazol was a 
gift from IPCA Laboratories Ltd, Ratlam, MP, 
India, while Pletoz
®
 50 tablets (cilostazol 
tablets 50 mg) manufactured by Hetero 
Drugs Ltd, Hyderabad were procured from a 
local pharmacy. Methanol AR grade (Merck, 
India) and distilled water were used for 
analytical work. 
 
Linear regression equation method 
 
Stock A (500 µg/ml cilostazol) was prepared 
from accurately weighed 50 mg cilostazol WS 
in 50 % aqueous methanol. It was diluted 
with the solvent to produce Stock B (50 
µg/ml); aliquots of Stock B were further 
diluted to give concentrations of 5, 10, 15, 20 
and 25 µg/ml of cilostazol, respectively. 
These dilutions were scanned from 300 to 
200 nm against 50 % aqueous methanol as 
blank, and their absorbances observed at 
258.2 nm.  
 
Standard absorptivity method 
 
Five dilutions of cilostazol were prepared in 
triplicate and their absorbances were 
observed at 258.2 nm. From the above 
observations, the standard absorptivity, A 
(1%, 1cm), and molar extinction coefficient 
were calculated. 
 
Validation of methods 
 
As per ICH guidelines [8-9], six dilutions in 
triplicate were used to validate both methods 
for linearity, accuracy (by recovery studies-
standard addition to pre-analysed samples), 
repeatability (within day), intermediate 
precision (days, analyst and instrument 
variation) and robustness (methanol 
variation: 45, 50 and 55 %), and statistical 




Twenty cilostazol tablets were weighed and 
finely powdered; a quantity equivalent to 50 
mg of cilostazol was dissolved in 100 ml of 50 
% aqueous methanol and filtered through 
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Whatman filter paper no. 41 to give Stock P. 
Stock P was diluted to obtain Stock Q (50 
µg/ml). Aliquots of Stock Q were diluted to 
obtain sample concentrations in the range of 
linearity. The absorbance values of these 
sample solutions were observed in a multi-
point calibration curve of quantitative mode at 
the selected wavelength (258.2 nm) to obtain 




The linear regression equation obtained from 
analyzing standard solutions of cilostazol is 
shown in Eq 1. 
 
ABC = 0.2069C - 0.204 ………………… (1) 
 
It showed an r
2
 = 0.9999 where ABC = 
absorbance, C = concentration (µg/ml), and r
2
 
= correlation coefficient. The standard 
absorptivity, A (1%, 1cm), and molar 











respectively (see Table 1). These developed 
methods were validated for various 
parameters, viz, accuracy, precision 
(repeatability, intermediate precision for days, 
instrument and analysts) and robustness. 
Statistical analysis (SD, CV, SEx and SEσ) 
for validation parameters are summarized in 
Table 2. These parameters were less than 
one. Thus, these parameters show the 
suitability of the methods. 
 
Table 1: Standard absorptivity, A (1%, 1cm), and 
molar extinction coefficient (ε) for cilostazol 
 
Absorbance at 258.2 
nm 
Standard absorptivity  
{A (1%, 1cm) = A/bc} Conc. 
(µg/ml) 




































A (1%, 1 cm)*     420.23 dlg-1cm-1 
ε **     15527.5 1 Mol-1cm-1 
* Mean of 15 standard absorptivity determinations; 
**Molar  extinction coefficient ε = A (1%, 1cm) Molecular 
weight/10 
 





SD CV SEx SEσ 




I.  Repeatability 
II. Intermediate                   
precision 
a.  Days 
b.  Analysts 




















































Standard absorptivity (SA) method 
Accuracy  
Precision 
I.  Repeatability 



















































* mean of six dilutions in triplicate; SD = standard deviation; CV = coefficient of variance; SEx = standard error of 
mean; and SEσ = standard error of standard deviation. 
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LRE = linear regression equation method and SA = standard absorptivity method 
 
 
The validated methods were applied to 
determine cilostazol in tablet dosage form, 
and the results were 101.23 % (SD = 0.611) 
by LRE method, and 99.96 % (SD = 0.592) 
by SA method. Mean of standard deviation 
(SEx) and standard error of standard 
deviation (SEσ) were far less than acceptable 
limits (see Table 3). Value of coefficient of 





The linear regression equation and standard 
absorptivity methods have been validated as 
per ICH guidelines, and results of validation 
parameters were within acceptable limits. 
Cilostazol was estimated by LRE and SA 
methods in tablet dosage form with standard 
deviation of 0.611 and 0.592, respectively. 
On comparing the two methods using the F-
test, the calculated value of F (1.065) was 
substantially less than the theoretical value at 
99 % confidence value; therefore, the 
methods have comparable precision. 
Impurities or any other interfering substances 
with λmax close to that of cilostazol (258.2 nm) 
would adversely affect the accuracy of the 
developed methods.. Further study on 
possible interfering substances will need to 




The developed methods for cilostazol are 
simple, rapid and economical with acceptable 
accuracy, precision, reproducibility and are 
robust to slight variations in experimental 
conditions. Thus, the validated methods may 
be used for routine analysis of cilostazol as 
the bulk drug and in tablets and other dosage 
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